Nonbiological pharmacotherapies for the treatment of diabetic macular edema

Aniruddha Agarwal, Jacob Parriott, Sibel Demirel, Colby Argo, Yasir Jamal Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety. The index review focuses on nonbiological therapies that have entered in phase 3 clinical trials for DME.Areas covered: An extensive review of the literature was performed to identify various nonbiological immunotherapies i.e., drugs other than -mAbs (monoclonal antibodies including anti-VEGF agents), -mibs (proteasome inhibitors), -NAbs (nanoparticle albumin-bound), and -nibs (small molecule inhibitor/tyrosine kinase inhibitors), among others. Extended-release low-dose corticosteroid devices have been recently approved for the treatment of DME. Other compounds such as non-steroidal anti-inflammatory drugs, antibody mimetic proteins, nonbiological growth factor inhibitors, and inhibitors of protein kinase C have been described.Expert opinion: A number of therapies are under development for the pharmacological management of DME. Due to the rising healthcare costs associated with anti-VEGF agents, a number of alternate treatment options have been explored recently. Some of these agents have reached phase 3 in clinical trials and appear to have a promising role in the management of DME. As further research is conducted, the role of each individual agent will become more defined, alone or in combination therapy.

Original languageEnglish (US)
Pages (from-to)2625-2635
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number17
DOIs
StatePublished - Nov 22 2015

Fingerprint

Macular Edema
Vascular Endothelial Growth Factors
Drug Therapy
Phase III Clinical Trials
Therapeutics
Growth Inhibitors
Proteasome Inhibitors
Expert Testimony
Pharmaceutical Preparations
Health Care Costs
Protein-Tyrosine Kinases
Immunotherapy
Nanoparticles
Protein Kinase C
Albumins
Intercellular Signaling Peptides and Proteins
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Monoclonal Antibodies
Pharmacology

Keywords

  • clinical trials
  • diabetic macular edema
  • nonbiological pharmacotherapy
  • nonsteroidal anti-inflammatory drugs
  • steroids

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Agarwal, A., Parriott, J., Demirel, S., Argo, C., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2015). Nonbiological pharmacotherapies for the treatment of diabetic macular edema. Expert Opinion on Pharmacotherapy, 16(17), 2625-2635. https://doi.org/10.1517/14656566.2015.1100172

Nonbiological pharmacotherapies for the treatment of diabetic macular edema. / Agarwal, Aniruddha; Parriott, Jacob; Demirel, Sibel; Argo, Colby; Sepah, Yasir Jamal; Do, Diana V.; Nguyen, Quan Dong.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 17, 22.11.2015, p. 2625-2635.

Research output: Contribution to journalReview article

Agarwal, A, Parriott, J, Demirel, S, Argo, C, Sepah, YJ, Do, DV & Nguyen, QD 2015, 'Nonbiological pharmacotherapies for the treatment of diabetic macular edema', Expert Opinion on Pharmacotherapy, vol. 16, no. 17, pp. 2625-2635. https://doi.org/10.1517/14656566.2015.1100172
Agarwal, Aniruddha ; Parriott, Jacob ; Demirel, Sibel ; Argo, Colby ; Sepah, Yasir Jamal ; Do, Diana V. ; Nguyen, Quan Dong. / Nonbiological pharmacotherapies for the treatment of diabetic macular edema. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 17. pp. 2625-2635.
@article{c525fa7b28144d1cb377e9df724db6d5,
title = "Nonbiological pharmacotherapies for the treatment of diabetic macular edema",
abstract = "Introduction: During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety. The index review focuses on nonbiological therapies that have entered in phase 3 clinical trials for DME.Areas covered: An extensive review of the literature was performed to identify various nonbiological immunotherapies i.e., drugs other than -mAbs (monoclonal antibodies including anti-VEGF agents), -mibs (proteasome inhibitors), -NAbs (nanoparticle albumin-bound), and -nibs (small molecule inhibitor/tyrosine kinase inhibitors), among others. Extended-release low-dose corticosteroid devices have been recently approved for the treatment of DME. Other compounds such as non-steroidal anti-inflammatory drugs, antibody mimetic proteins, nonbiological growth factor inhibitors, and inhibitors of protein kinase C have been described.Expert opinion: A number of therapies are under development for the pharmacological management of DME. Due to the rising healthcare costs associated with anti-VEGF agents, a number of alternate treatment options have been explored recently. Some of these agents have reached phase 3 in clinical trials and appear to have a promising role in the management of DME. As further research is conducted, the role of each individual agent will become more defined, alone or in combination therapy.",
keywords = "clinical trials, diabetic macular edema, nonbiological pharmacotherapy, nonsteroidal anti-inflammatory drugs, steroids",
author = "Aniruddha Agarwal and Jacob Parriott and Sibel Demirel and Colby Argo and Sepah, {Yasir Jamal} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "11",
day = "22",
doi = "10.1517/14656566.2015.1100172",
language = "English (US)",
volume = "16",
pages = "2625--2635",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - Nonbiological pharmacotherapies for the treatment of diabetic macular edema

AU - Agarwal, Aniruddha

AU - Parriott, Jacob

AU - Demirel, Sibel

AU - Argo, Colby

AU - Sepah, Yasir Jamal

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/11/22

Y1 - 2015/11/22

N2 - Introduction: During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety. The index review focuses on nonbiological therapies that have entered in phase 3 clinical trials for DME.Areas covered: An extensive review of the literature was performed to identify various nonbiological immunotherapies i.e., drugs other than -mAbs (monoclonal antibodies including anti-VEGF agents), -mibs (proteasome inhibitors), -NAbs (nanoparticle albumin-bound), and -nibs (small molecule inhibitor/tyrosine kinase inhibitors), among others. Extended-release low-dose corticosteroid devices have been recently approved for the treatment of DME. Other compounds such as non-steroidal anti-inflammatory drugs, antibody mimetic proteins, nonbiological growth factor inhibitors, and inhibitors of protein kinase C have been described.Expert opinion: A number of therapies are under development for the pharmacological management of DME. Due to the rising healthcare costs associated with anti-VEGF agents, a number of alternate treatment options have been explored recently. Some of these agents have reached phase 3 in clinical trials and appear to have a promising role in the management of DME. As further research is conducted, the role of each individual agent will become more defined, alone or in combination therapy.

AB - Introduction: During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety. The index review focuses on nonbiological therapies that have entered in phase 3 clinical trials for DME.Areas covered: An extensive review of the literature was performed to identify various nonbiological immunotherapies i.e., drugs other than -mAbs (monoclonal antibodies including anti-VEGF agents), -mibs (proteasome inhibitors), -NAbs (nanoparticle albumin-bound), and -nibs (small molecule inhibitor/tyrosine kinase inhibitors), among others. Extended-release low-dose corticosteroid devices have been recently approved for the treatment of DME. Other compounds such as non-steroidal anti-inflammatory drugs, antibody mimetic proteins, nonbiological growth factor inhibitors, and inhibitors of protein kinase C have been described.Expert opinion: A number of therapies are under development for the pharmacological management of DME. Due to the rising healthcare costs associated with anti-VEGF agents, a number of alternate treatment options have been explored recently. Some of these agents have reached phase 3 in clinical trials and appear to have a promising role in the management of DME. As further research is conducted, the role of each individual agent will become more defined, alone or in combination therapy.

KW - clinical trials

KW - diabetic macular edema

KW - nonbiological pharmacotherapy

KW - nonsteroidal anti-inflammatory drugs

KW - steroids

UR - http://www.scopus.com/inward/record.url?scp=84951907751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951907751&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1100172

DO - 10.1517/14656566.2015.1100172

M3 - Review article

C2 - 26523670

AN - SCOPUS:84951907751

VL - 16

SP - 2625

EP - 2635

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -